Equity Overview
Price & Market Data
Price: $4.17
Daily Change: +$0.175 / 4.20%
Daily Range: $3.90 - $4.20
Market Cap: $25,960,034
Daily Volume: 68,166
Performance Metrics
1 Week: -1.66%
1 Month: -1.19%
3 Months: -26.47%
6 Months: 273.0%
1 Year: 116.8%
YTD: 104.0%
Company Details
Employees: 2
Sector: Health technology
Industry: Biotechnology
Country:
Details
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.